Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients

Postgraduate Medicine

Volumn 126, Issue 5, 2014, Pages 128-134

  Evans, John D ^a   Udeani, George ^a   Cole, Phillip ^b   Friedland, H David ^b  

^a Christus Spohn Hospital   (United States)

^b Cerexa Inc   (United States)

Author keywords

ABSSSI; CAPTURE; Ceftaroline fosamil; Obesity; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ADOLESCENT; ADULT; AGE; AGED; FEMALE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SKIN DISEASES, BACTERIAL; SOCIOECONOMICS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; OBESITY; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; SEX FACTORS; SKIN DISEASES, BACTERIAL; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84921824873     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.09.2807     Document Type: Article

References (18)

1. Genoni G, Prodam F, Marolda A, et al. Obesity and infection: two sides of one coin. Eur J Pediatr. 2014;173(1):25-32.
2. Huttunen R, Karppelin M, Syrjänen J. Obesity and nosocomial infections. J Hosp Infect. 2013;85(1):8-16.
3. Khawcharoenporn T, Tice AD, Grandinetti A, Chow D. Risk factors for community-associated methicillin-resistant Staphylococcus aureus cellulitis-and the value of recognition. Hawaii Med J. 2010;69(10):232-236.
4. Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970-976.
5. Al-Dorzi HM, Al Harbi SA, Arabi YM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis. 2014;27(2):165-173.
6. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52(9):3398-3407.
7. Kaushik D, Rathi S, Jain A. Ceftaroline: a comprehensive update. Int J Antimicrob Agents. 2011;37(5):389-395.
8. International Conference on Harmonisation E6 Good Clinical Practice guidance. Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), 5600 Fishers Lane, Rockville, MD 20857. 1976. http://www.fda.gov/downloads/Drugs/Guidance/ucm073122.pdf.
9. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56(6):901-916.
10. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37(3):333-340.
11. Gunderson CG. Cellulitis: definition, etiology, and clinical features. Am J Med. 2011;124(12):1113-1122.
12. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64(2):148-155.
13. Guh DP, Zhang W, Bansback N, Amarsi Z, Laird Birmingham C, Amis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9(Mar 25):88.
14. Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity. Diabetes Care. 2011;34(7):1642-1647.
15. File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(Suppl 3): S173-S180.
16. Stryjewski ME, Barriere SL, O'Riordan W, et al. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012;67(6):1496-1502.
17. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368-375.
18. Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc Nephrol. 2006;1(5):1117-1123.